L. Ohrmund

发表

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

P. Rutgeerts, S. Vermeire, A. Gils, 2013, The American Journal of Gastroenterology.

Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.

E. Chuang, Sharat Singh, R. Shringarpure, 2013, Journal of pharmaceutical and biomedical analysis.

565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)

L. Croner, G. Greenberg, P. Rutgeerts, 2012 .

The relationship between in fl iximab concentrations , antibodies to in fl iximab and disease activity in Crohn ’ s disease

G. Greenberg, P. Rutgeerts, S. Vermeire, 2014 .

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

G. Greenberg, L. Stitt, W. Sandborn, 2014, Alimentary pharmacology & therapeutics.

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

G. Greenberg, P. Rutgeerts, S. Vermeire, 2014, Gut.

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.

Sharat Singh, Sharat Singh, S. Hauenstein, 2012, Journal of immunological methods.

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

K. Mcfarland, D. Bonhaus, J. Lameh, 2010, Neuropharmacology.

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

P. Rutgeerts, S. Vermeire, A. Gils, 2013, The American Journal of Gastroenterology.

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

K. Mcfarland, D. Bonhaus, J. Lameh, 2010, Neuropharmacology.